XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher

MT Newswires Live06-12

XOMA (XOMA) said Wednesday it has received an $8.1 million milestone payment related to the sale by Day One Biopharmaceuticals (DAWN) of its Priority Review Voucher to an undisclosed buyer for $108 million.

XOMA said it received the payment from Viracta Therapeutics (VIRX), to which it paid $13.5 million in March 2021 to acquire up to $54 million in potential milestones and mid-single digit royalties associated with cancer drug Ojemda and economics associated with vosaroxin.

XOMA Chief Executive Owen Hughes said the company expects future royalties on Ojemda to add to a portfolio of royalty receipts that will support the company's free cash flow generation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2442155572?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-12 20:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2442155572","market":"sh","top_or_hot":-1,"title":"XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher","media":"MT Newswires Live","content":"<html><body><p> XOMA (XOMA) said Wednesday it has received an $8.1 million milestone payment related to the sale by Day One Biopharmaceuticals (DAWN) of its Priority Review Voucher to an undisclosed buyer for $108 million.</p><p>XOMA said it received the payment from Viracta <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (VIRX), to which it paid $13.5 million in March 2021 to acquire up to $54 million in potential milestones and mid-single digit royalties associated with cancer drug Ojemda and economics associated with vosaroxin.</p><p>XOMA Chief Executive Owen Hughes said the company expects future royalties on Ojemda to add to a portfolio of royalty receipts that will support the company's free cash flow generation.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-12 20:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>XOMA (XOMA) said Wednesday it has received an $8.1 million milestone payment related to the sale by Day One Biopharmaceuticals (DAWN) of its Priority Review Voucher to an undisclosed buyer for $108 ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2442155572","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2442155572","pubTimestamp":1718195872,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"XOMA  said Wednesday it has received an $8.1 million milestone payment related to the sale by Day One Biopharmaceuticals  of its Priority Review Voucher to an undisclosed buyer for $108 million.XOMA said it received the payment from Viracta Therapeutics , to which it paid $13.5 million in March 2021 to acquire up to $54 million in potential milestones and mid-single digit royalties associated with cancer drug Ojemda and economics associated with vosaroxin.XOMA Chief Executive Owen Hughes said the company expects future royalties on Ojemda to add to a portfolio of royalty receipts that will support the company's free cash flow generation.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","DAWN":"Day One Biopharmaceuticals Inc.","VIRX":"Viracta Therapeutics, Inc.","XOMA":"标记临床研究"},"translate_title":"XOMA获得与出售优先审查券相关的810万美元里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XOMA":1,"DAWN":0.9,"VIRX":0.9},"content_text":"XOMA (XOMA) said Wednesday it has received an $8.1 million milestone payment related to the sale by Day One Biopharmaceuticals (DAWN) of its Priority Review Voucher to an undisclosed buyer for $108 million.XOMA said it received the payment from Viracta Therapeutics (VIRX), to which it paid $13.5 million in March 2021 to acquire up to $54 million in potential milestones and mid-single digit royalties associated with cancer drug Ojemda and economics associated with vosaroxin.XOMA Chief Executive Owen Hughes said the company expects future royalties on Ojemda to add to a portfolio of royalty receipts that will support the company's free cash flow generation.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2442155572"}